A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №2 2025 год

more

A.I. Burnasyan  FMBC clinical bulletin. 2024 № 2

V.N. Yakimets1,2, E.N. Missyurina1, Jelnova.E.I.1, Tholstyh T.N.1, V.I. Bulygina2, T.A. Astrelina3

Covid-19 Coronavirus Infection in Patients with Multiple Myeloma:
Literature Review and Own Experience

1Moscow City Clinical Hospital 52, Moscow, Russiа

2Sechenov First Moscow State Medical Univesity Russia, Moscow

3International Office, State Research Center – Burnasyan Federal Medical Biophysical Center  of Federal Medical Biological Agency, Moscow, Russiа

Contact person: Astrelina Tatyana Alekseevna: t_astrelina@mail.ru

 

Abstract
The presented literature review presents studies, including our own, on the peculiarities of the course of coronavirus infection in patients with hemoblastosis, in particular in patients with multiple myeloma (MM). It has been shown that in patients with MM attachment of the SARS-CoV-2 COVID-19 coronavirus infection, the prognosis of the patient’s life significantly worsens, which makes significant changes in the overall survival and mortality rates. Factors that worsen the prognosis of life in patients with MM are old age, male gender, uncontrolled/active disease and/or high risk of MM, concomitant diseases, MM beyond remission, acute course of SARS-CoV-2 COVID19, interruption of treatment without subsequent resumption. Patients with MM are at high risk of severe coronavirus infection COVID-19 and mortality, however, this risk is lower compared to coronavirus infection SARS-CoV-2 and Delta. MM patients receiving anti-BCMA therapy do not respond to vaccination and have a risk of developing severe course and progression of coronavirus infection due to the lack of an immune response of some Omicron variants. Patients with MM should be vaccinated with updated mRNA-based booster vaccines adapted to Omicron. In case of COVID-19 coronavirus infection, patients with MM should be prescribed oral effective antiviral drugs or remdesivir. Treatment of SARS-CoV-2 COVID19 patients with MM should be carried out in full according to the clinical guidelines for the treatment of SARS-CoV-2 COVID19.

Keywords: multiple myeloma, SARS-CoV-2 coronavirus infection, COVID19, survival, death rate, factors

For citation: Yakimets VN, Missyurina EN, Jelnova.EI., Tholstyh TN,, V.I. Bulygina VI, Astrelina TA. Covid-19 Coronavirus Infection in Patients with Multiple Myeloma: Literature Review and Own Experience. A.I. Burnasyan Federal Medical iophysical Center Clinical Bulletin. 2024.2:44-52. (In Russian) DOI: 10.33266/2782-6430-2024-2-44-52

 

REFERENCES

  1. Менделеева Л.П., Вотякова О.М., Рехтина И.Г., и др. Множественная миелома. Клинические рекомендации // Современная Онкология. 2020. Т. 22, № 4. С. 6–28. [Mendeleyeva L.P., Votyakova O.M., Rekhtina I.G., et al. Multiple Myeloma. Clinical Guidelines. Sovremennaya Onkologiya = Journal of Modern Oncology. 2020;22;4:6–28 (In Russ.)]. DOI: 10.26442/18151434.2020.4.200457.
  2. Ludwig H., Delforge M., Facon T., et al. Prevention and Management of Adverse Events of Novel Agents in Multiple Myeloma: A Consensus of the European Myeloma Network. Leukemia. 2017;18. doi: 10.1038/leu.2017.353.
  3. Ivana von Metzler I., Campe J., Huenecke S., et al. COVID-19 in Multiple-Myeloma Patients: Cellular and Humoral Immunity Against SARSCoV-2 in a Short- and Long-Term View. J Mol Medм (Berl). 2022;100;3:463-470. doi: 10.1007/ s00109-021-02114-x.
  4. Blimark C., Holmberg E., Mellqvist UH., et al. Multiple Myeloma and Infections: a Populationbased Study on 9253 Multiple Myeloma Patients. Haematologica. 2015;100;1:107-13. doi: 10.3324/haematol.2014.107714.
  5. Blimark C., Holmberg E., Mellqvist UH., Landgren O., Bjorkholm M., Hultcrantz M., et al. Multiple Myeloma and Infections: a Population-Based Study on 9253 Multiple Myeloma Patients. Haematologica. 2015;100:107–113.
  6. Sorrig R., Klausen T.W., Salomo M., Vangsted A., Gimsing P. Risk Factors for Infections in Newly Diagnosed Multiple Myeloma Patients: a Danish Retrospective Nationwide Cohort Study. Eur J Haematol. 2019;102:182–90.
  7. Raje N.S., Anaissie E., Kumar S.K., Lonial S., Martin T., Gertz M.A., et al. Consensus Guidelines and Recommendations for Infection Prevention in Multiple Myeloma: a Report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143–61.
  8. Ho M., Zanwar S., Buadi F.K., Ailawadhi S., Larsen J., Bergsagel L., et al. Risk Factors for Severe Infection and Mortality in Patients with COVID-19 in Patients with Multiple Myeloma and AL Amyloidosis. Am J Hematol. 2023;98:49–55.
  9. Chen M., Zhao Y., Xu C., Wang X., Zhang X., Mao B. Immunomodulatory Drugs and the Risk of Serious Infection in Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized and Observational Studies. Ann Hematol. 2018;97:925–944.
  10. Basler M., Lauer C., Beck U., Groettrup M. The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection. J Immunol. 2009;183:6145–6150.
  11. Nahi H., Chrobok M., Gran C., Lund J., Gruber A., Gahrton G., et al. Infectious Complications and NK Cell Depletion Following Daratumumab Treatment of Multiple Myeloma. PLoS One. 2019;14:e0211927.
  12. Zhou D., Wang Y., Cheng H., Zhu L., Chen W., Li H., et al. Factors Associated with Infection Events after Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Multiple Myeloma. J. Infect Chemother. 2023;29:179–185.
  13. Ludwig H., Boccadoro M., Moreau P., San-Miguel J., Cavo M., Pawlyn C., et al. Recommendations for Vaccination in Multiple Myeloma: a Consensus of the European Myeloma Network. Leukemia. 2021;35:31–44.
  14. Terpos E., Engelhardt M., Cook G., Gay F., Mateos M.V., Ntanasis-Stathopoulos I., et al. Management of Patients with Multiple Myeloma in the Era of COVID-19 Pandemic: a Consensus Paper from the European Myeloma Network (EMN) Leukemia. 2020;34:2000–2011.
  15. Martinez-Lopez J., Hernandez-Ibarburu G., Alonso R., Sanchez-Pina J.M., Zamanillo I., Lopez-Munoz N., et al. Impact of COVID-19 in Patients with Multiple Myeloma Based on a Global Data Network. Blood Cancer J. 2021;11:198.
  16. Pagano L., Salmanton-Garcia J., Marchesi F., Busca A., Corradini P., Hoenigl M., et al. COVID-19 Infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) J Hematol Oncol. 2021;14:168.
  17. Song Q., Bates B., Shao YR., Hsu FC., Liu F., Madhira V., et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients with Cancer: Real-World Evidence from the National COVID Cohort Collaborative. J Clin Oncol. 2022;40:1414–27.
  18. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720.
  19. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
  20. Yousif E., Premraj S. A Review of Long COVID with a Special Focus on Its Cardiovascular Manifestations. Cureus. 2022.
  21. Patel U.K., Mehta N., Patel A., Patel N., Ortiz J.F., Khurana M., et al. Long-Term Neurological Sequelae among Severe COVID-19 Patients: a Systematic Review and Meta-Analysis. Cureus. 2022.
  22. Korompoki E., Gavriatopoulou M., Hicklen R.S., Ntanasis-Stathopoulos I., Kastritis E., Fotiou D., et al. Epidemiology and Organ Specific Sequelae of Post-Acute COVID19: a Narrative Review. J Infect. 2021;83:1–16.
  23. Korompoki E., Gavriatopoulou M., Fotiou D., Ntanasis-Stathopoulos I., Dimopoulos MA., Terpos E. Late-Onset Hematological Complications Post COVID-20: an Emerging Medical Problem for the Hematologist. Am. J. Hematol. 2022;97:119–28.
  24. Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., et al. Clinical Characteristics and Risk Factors Associated with COVID-19 Severity in Patients with Haematological Malignancies in Italy: a Retrospective, Multicentre, Cohort Study. Lancet Haematol. 2020:737–745.
  25. Martínez-López J., Mateos MV., Encinas C., et al. Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality. Blood Cancer J. 2020;10;10:103. doi: 10.1038/s41408-020-00372-5.
  26. Padala S.A., Barsouk A., Barsouk A., et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci. (Basel). 2021;9;1:3. doi: 10.3390/medsci9010003.
  27. Hultcrantz M., Richter J., Rosenbaum C., et al. COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: a Cohort Study from Five Academic Centers. MedRxiv [Preprint]. 2020:2020.06.09.20126516. doi: 10.1101/2020.06.09.20126516.
  28. Liang W., Guan W., Chen R., et al. Cancer Patients in SARS-CoV-2 Infection: a Nationwide Analysis in China. Lancet Oncol. 2020;21;3:335-337. doi: 10.1016/S1470-2045(20)30096-6.
  29. Dai M., Liu D., Liu M., et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study During the COVID-19 Outbreak. Cancer Discov. 2020;10;6:783-791. doi:10.1158/2159-8290.CD-20-0422.
  30. Martinez-Lopez J., Hernandez-Ibarburu G., Alonso R., et al. Impact of COVID-19 in Patients with Multiple Myeloma Based on a Global Data Network. Blood Cancer J. 2021;11;12:198. doi:10.1038/s41408-021-00588-z.
  31. Chari A., Samur MK., Martinez-Lopez J., et al. Clinical Features Associated with COVID-19 Outcome in Multiple Myeloma: First Results from the International Myeloma Society Data Set. Blood. 2020;136;26:3033-3040. doi: 10.1182/ blood.2020008150.
  32. Munshi N.C., Anderson K.C. Don’t Compromise Myeloma Care Due to COVID-19 Pandemic!. Blood Cancer Discov. 2020;1;3:218-220. doi:10.1158/2643-3230.BCD- 20-0151.
  33. Salje H., Tran Kiem C., Lefrancq N., et al. Estimating the Burden of SARS-CoV-2 in France. Science. 2020;369;6500:208-211.
  34. Haitao T., Vermunt JV., Abeykoon J., et al. COVID-19 and Sex Differences: Mechanisms and Biomarkers. Mayo Clin Proc. 2020;95;10:2189-2203. doi: 10.1016/j.mayocp.2020.07.024.
  35. Wang B., Van Oekelen O., Mouhieddine T.H., et al. A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward. J. Hematol Oncol. 2020;13;1:94. doi:10.1186/s13045-020-00934-x.
  36. Krejci M., Pour L., Adam Z., et al. Outcome of COVID-19 Infection in 50 Multiple Myeloma Patients Treated with Novel Drugs: Single-Center Experience. Ann Hematol. 2021;100;10:2541-2546. doi:10.1007/s00277-021-04594-w.
  37. Pinato D.J., Zambelli A., Aguilar-Company J., et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Cancer Patients. Cancer Discov. 2020;10;10:1465–1474. doi: 10.1158/2159-8290.CD-20-0773.
  38. Rivera D.R., Peters S., Panagiotou OA., et al. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: a COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020;10;10:1514-1527. doi: 10.1158/2159-8290.CD-20-0941.
  39. Engelhardt M., Shoumariyeh K., Rösner A., et al. Clinical Characteristics and Outcome of Multiple Myeloma Patients with Concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica. 2020;105;12:2872-2878. doi: 10.3324/haematol.2020.262758.
  40. Liu C., Zhao Y., Okwan-Duodu D., Basho R., Cui X. COVID-19 in Cancer Patients: Risk, Clinical Features, and Management. Cancer Biol Med. 2020;17;3:519-527. doi: 10.20892/j.issn.2095-3941.2020.0289.
  41. Huang C.T., Liu C.J., Ko P.S., et al. Risk Factors and Characteristics of Blood Stream Infections in Patients with Newly Diagnosed Multiple Myeloma. BMC Infect Dis. 2017;17;1:33. doi: 10.1186/s12879-016-2155-1.
  42. Kuderer N.M., Choueiri T.K., Shah D.P., et al. Clinical Impact of COVID-19 on Patients with Cancer (CCC19): a Cohort Study. Lancet. 2020;39;10241:1907-1918.
  43. Ajai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez et al. Clinical Features Associated with COVID-19 Outcome in Multiple Myeloma: First Results from the International Myeloma Society Data Set. Blood. 2020;136;26:3033-3040. doi: 10.1182/blood.2020008150.
  44. Pagano L. EPICOVIDEHA Survey: COVID-19 Infections in Patients with Haematological Malignancies – Results from EHA-IDWP Registry. European Hematology Association 2021 Virtual Congress; Jun 9–17, 2021; Virtual.
  45. Salmanton-García J. Busca A. Cornely O.A., et al. EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients with COVID-19. HemaSphere. 2021;5;7:e612. DOI: 1097/HS9.0000000000000612.
  46. Heinz Ludwig, Pieter Sonneveld, Thierry Facon, et al. COVID-19 Vaccination in Patients with Multiple Myeloma: a Consensus of the European Myeloma Network. The Lancet. 2021;8;12:E934-E946 DOI:https://doi.org/10.1016/S2352-3026(21)00278/.
  47. Nico Gagelmann, Francesco Passamonti, Christine Wolschke et al. Antibody Response after Vaccination Against SARS-CoV-2 in Adults with Hematological Malignancies: a Systematic Review and Meta-Analysis. Haematologica. 2022;107;8:1840-1849. DOI: 10.3324/гематол.2021.280163.
  48. Mahya Shabani, Parnian Shobeiri, Shadi Nouri, Zahra Moradi, Robel Assefa Amenu, Mohammad-Mehdi Mehrabi Nejad & Nima Rezaei. Risk of Flare or Relapse in Patients with Immune-Mediated Diseases Following SARS-CoV-2 Vaccination: a Systematic Review and Meta-Analysis. European Journal of Medical Research. 2024;29:55.
  49. Faustini S.E., Hall A., Brown S., Roberts S., Hill H., Stamataki Z., (PITCH) consortium, Jenner M.W., Owen R.G., Pratt G., Cook G., Richter A., Drayson M.T., Kaiser M.F., Heaney J.L.J., Faustini S.E., et al. Immune Responses to COVID-19 Booster Vaccinations in Intensively Anti-CD38 Antibody Treated Patients with Ultra-High-Risk Multiple Myeloma: Results from the Myeloma UK (MUK) Nine OPTIMUM Trial. Br J Haematol. 2023;201;5:845-850. doi: 10.1111/bjh.18714.
  50. Галанин В.В., Демко И.В., Бахтина В.И., Гордо А.А., Белоногов Д.В., Кочергина Е.С. COVID-19 инфекция у пациентов с множественной миеломой (обзорная статья) // Бюллетень медицинской науки. 2022. Т. 4, № 28. C. 116-127. [Galanin V.V., Demko I.V., Bakhtina V.I., Gordo A.A., Belonogov D.V., Kochergina E.S. COVID-19 Infection in Patients with Multiple Myeloma (Review Article). Byulleten’ Medicinskoy Nauki. 2022;4;28:116-127 (In Russ.)].
  51. Якимец В.Н., Желнова Е.И., Мисюрина Е.Н. и др. Клинические особенности и тактика лечения больных множественной миеломой во время пандемии COVID‑19. Онкогематология. 2023. Т. 18, № 4. С. 86–90. [Yakimets V.N., Zhelnova E.I., Misyurina E.N., et al. Clinical Features and Treatment Strategy for Patients with Multiple Myeloma During the COVID-19 Pandemic. Onkogematologiya = Oncohematology. 2023;18;4:86–90 (In Russ.)]. DOI: https://doi.org/10.17650/1818‑8346‑2023‑ 18‑4(Suppl)‑86‑90.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship. 
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.03.2024. Accepted for publication: 16.04.2024

© 2025 Scientific journal - "Clinical Bulletin of the FMBС im. A.I. Burnasyan"
Scroll to Top